Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?


Gungor O., Sevinc M., Ulu S., KOÇYİĞİT İ.

International Urology and Nephrology, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Publication Date: 2022
  • Doi Number: 10.1007/s11255-022-03393-0
  • Journal Name: International Urology and Nephrology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
  • Keywords: Sarcopenia, Cardiovascular disease, Kidney patients, Muscle, Kidney, SKELETAL-MUSCLE MASS, ARTERIAL STIFFNESS, DOUBLE-BLIND, GRIP STRENGTH, OLDER-ADULTS, ASSOCIATION, RISK, MORTALITY, RESISTANCE, ADIPOSITY
  • Kayseri University Affiliated: No

Abstract

© 2022, The Author(s), under exclusive licence to Springer Nature B.V.Cardiovascular disease (CVD) incidence is high in patients with chronic kidney disease (CKD) and is the most frequent cause of mortality in this population. Advanced age, hypertension, uremic toxins, endothelial dysfunction, atherosclerosis, hyperhomocysteinemia, oxidative stress, and inflammation are among the leading causes of increased CVD in advanced stages of CKD. Although defined as a decrease in muscle strength associated with aging, sarcopenia is also prevalent in CKD patients. Sarcopenia causes physical disability, low quality of life, and mortality. Regular exercise and nutritional supplementation may slow the progression of sarcopenia. Recent studies have shown that sarcopenia increases the risk of CVD and mortality in people with or without kidney disease. This review discusses the relationship between sarcopenia and CVD in light of the current literature.